Predicting the Probability of Experiencing Clinically Significant Drug–Drug Interactions Involving Boceprevir-Containing Hepatitis C Therapy Among Patients Coinfected with Hepatitis C and HIV
Restricted accessResearch articleFirst published online October, 2014
Predicting the Probability of Experiencing Clinically Significant Drug–Drug Interactions Involving Boceprevir-Containing Hepatitis C Therapy Among Patients Coinfected with Hepatitis C and HIV
RotmanY, LiangTJ. Coinfection with hepatitis C virus and human immunodeficiency virus: Virological, immunological, and clinical outcomes. J Virol, 2009; 83:7366–7374.
2.
MandorferM, PayerBA, NiedereckerA, et al.Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. AIDS Patient Care STDs, 2014; 28:221–227.
3.
American Association for the Study of Liver Diseases, Infectious Diseases Society of America and International AIDS Society–USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org (Last accessed May15, 2014).
4.
SievertW, AltraifI, RazaviHA, et al.A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int, 2011; 31Suppl 2:61–80.
5.
PatelN, VeveM, BlissS, et al.Prevalence and predictors of important telaprevir drug interactions among patients coinfected with hepatitis C and human immunodeficiency virus. J Pharm Technol, 2014:1–9.
6.
McNuttLA, WuC, XueX, HafnerJP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol, 2003; 157:940–943.
7.
TsengA, SzadkowskiL, WalmsleyS, SalitI, RaboudJ. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother, 2013; 47:1429–1439.
8.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Last accessed May15, 2014).
9.
NainanOV, AlterMJ, Kruszon-MoranD, et al.Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology, 2006; 131:478–484.
10.
JonckheereS, VincentA, BelkhirL, WilmesD, VandercamB, YombiJC. Adherence to screening guidelines for hepatitis C among HIV-positive patients. AIDS Patient Care STDs, 2013; 27:317–319.
